Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 2
2008 2
2009 2
2010 6
2011 12
2012 9
2013 11
2014 12
2015 8
2016 16
2017 13
2018 18
2019 15
2020 13
2021 18
2022 15
2023 15
2024 12
2025 10
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

187 results

Results by year

Filters applied: . Clear all
Page 1
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial.
Marth C, Moore RG, Bidziński M, Pignata S, Ayhan A, Rubio MJ, Beiner M, Hall M, Vulsteke C, Braicu EI, Sonoda K, Wu X, Frentzas S, Mattar A, Lheureux S, Chen X, Hasegawa K, Magallanes-Maciel M, Choi CH, Shalkova M, Kaen D, Wang PH, Berger R, Okpara CE, McKenzie J, Yao L, Orlowski R, Khemka V, Gilbert L, Makker V; ENGOT-en9/LEAP-001 Investigators. Marth C, et al. Among authors: braicu ei. J Clin Oncol. 2025 Mar 20;43(9):1083-1100. doi: 10.1200/JCO-24-01326. Epub 2024 Nov 26. J Clin Oncol. 2025. PMID: 39591551 Free PMC article. Clinical Trial.
Practical Guidelines for the Treatment of Gestational Trophoblastic Disease: Collaboration of the European Organisation for the Treatment of Trophoblastic Disease (EOTTD)-European Society of Gynaecologic Oncology (ESGO)-Gynecologic Cancer InterGroup (GCIG)-International Society for the Study of Trophoblastic Diseases (ISSTD).
Lok C, van Trommel N, Braicu EI, Planchamp F, Berkowitz R, Seckl M; EOTTD-ESGO-GCIG-ISSTD Guideline Committee. Lok C, et al. Among authors: braicu ei. J Clin Oncol. 2025 Jun 20;43(18):2119-2128. doi: 10.1200/JCO-24-02326. Epub 2025 May 13. J Clin Oncol. 2025. PMID: 40359461 Free article.
Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer.
Arends CM, Kopp K, Hablesreiter R, Estrada N, Christen F, Moll UM, Zeillinger R, Schmitt WD, Sehouli J, Kulbe H, Fleischmann M, Ray-Coquard I, Zeimet A, Raspagliesi F, Zamagni C, Vergote I, Lorusso D, Concin N, Bullinger L, Braicu EI, Damm F. Arends CM, et al. Among authors: braicu ei. Leukemia. 2024 Jun;38(6):1378-1389. doi: 10.1038/s41375-024-02253-3. Epub 2024 Apr 18. Leukemia. 2024. PMID: 38637689 Free PMC article. Clinical Trial.
Circadian rhythm disruption by PARP inhibitors correlates with treatment toxicity in patients with ovarian cancer and is a predictor of side effects.
Malhan D, Hesse J, Nelson N, Stankov K, Nguyen J, Aboumanify O, Garmshausen J, Rogmans G, Czogalla B, Gerber J, Koch M, Kupec T, Tomé O, Witteler R, Deryal M, Eichbaum M, Sehouli J, Braicu EI, Relógio A. Malhan D, et al. Among authors: braicu ei. EBioMedicine. 2025 Jul;117:105764. doi: 10.1016/j.ebiom.2025.105764. Epub 2025 May 16. EBioMedicine. 2025. PMID: 40382284 Free PMC article. Clinical Trial.
Detection of ESR1 Mutations in Tissue and Liquid Biopsy with Novel Next-Generation Sequencing and Digital Droplet PCR Assays: Insights from Multi-Center Real Life Data of Almost 6000 Patients.
Borkar S, Markus F, Oetting A, Schmidt S, Vössing C, Horst D, Möbs M, Braicu EI, Griesinger F, Horling K, Tiemann K, Heukamp LC, Willing EM, Vollbrecht C. Borkar S, et al. Among authors: braicu ei. Cancers (Basel). 2025 Apr 9;17(8):1266. doi: 10.3390/cancers17081266. Cancers (Basel). 2025. PMID: 40282442 Free PMC article.
NSGO-FANDANGO/ENGOT-EN1: A randomized phase II study of first-line combination chemotherapy with nintedanib/placebo in advanced/recurrent endometrial cancer.
Lindemann K, Berton D, Sehouli J, Christensen RD, Altintas S, Knudsen AØ, Heudel PE, Ataseven B, Vergote I, Lindahl G, Lebreton C, Schochter F, Auranen A, Follana P, Madsen K, Selle F, Petersson KS, Joly F, Braicu EI, Mirza MR. Lindemann K, et al. Among authors: braicu ei. Gynecol Oncol. 2025 Aug;199:79-87. doi: 10.1016/j.ygyno.2025.06.008. Epub 2025 Jun 30. Gynecol Oncol. 2025. PMID: 40592025 Clinical Trial.
187 results